Key Points
- Director David Dalvey sold 20,000 shares on Jan. 27 at an average price of $120.03 for roughly $2.40 million, reducing his stake by 18.18% to 90,000 shares (about $10.8M).
- CELC price context: the stock opened at $112.12, trades in a 52‑week range of $7.57–$120.32, has a $5.19B market cap and 50/200‑day moving averages of $104.00 and $71.07, indicating a sharp recent run‑up.
- Analyst and institutional activity: consensus is a "Moderate Buy" with an average target of $105.25 and several upgrades (Jefferies $134, Stifel $115), while institutions own ~63.33% and firms like UBS and Apis have added large stakes.
Celcuity, Inc. (NASDAQ:CELC - Get Free Report) Director David Dalvey sold 20,000 shares of the stock in a transaction that occurred on Tuesday, January 27th. The stock was sold at an average price of $120.03, for a total value of $2,400,600.00. Following the completion of the sale, the director owned 90,000 shares in the company, valued at approximately $10,802,700. The trade was a 18.18% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.
Celcuity Price Performance
CELC opened at $112.12 on Friday. The business has a fifty day moving average of $104.00 and a 200 day moving average of $71.07. The stock has a market cap of $5.19 billion, a P/E ratio of -30.55 and a beta of 0.25. The company has a quick ratio of 12.26, a current ratio of 12.26 and a debt-to-equity ratio of 2.74. Celcuity, Inc. has a 52-week low of $7.57 and a 52-week high of $120.32.
Celcuity (NASDAQ:CELC - Get Free Report) last released its earnings results on Wednesday, November 12th. The company reported ($0.92) earnings per share for the quarter, topping analysts' consensus estimates of ($1.05) by $0.13. As a group, sell-side analysts anticipate that Celcuity, Inc. will post -2.62 EPS for the current year.
Analyst Upgrades and Downgrades
CELC has been the topic of a number of research analyst reports. Jefferies Financial Group upped their target price on shares of Celcuity from $108.00 to $134.00 and gave the stock a "buy" rating in a research note on Tuesday, December 2nd. Stifel Nicolaus increased their price objective on Celcuity from $68.00 to $115.00 and gave the stock a "buy" rating in a research note on Thursday, November 13th. Wall Street Zen lowered Celcuity from a "hold" rating to a "sell" rating in a research report on Sunday, October 26th. Needham & Company LLC set a $95.00 target price on Celcuity in a report on Monday, October 20th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Celcuity in a research note on Wednesday, January 21st. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $105.25.
Check Out Our Latest Report on CELC
Hedge Funds Weigh In On Celcuity
Large investors have recently modified their holdings of the stock. Apis Capital Advisors LLC bought a new stake in shares of Celcuity during the 3rd quarter worth about $38,334,000. UBS Group AG boosted its holdings in shares of Celcuity by 910.1% during the third quarter. UBS Group AG now owns 854,483 shares of the company's stock worth $42,211,000 after acquiring an additional 769,891 shares during the period. Deerfield Management Company L.P. acquired a new position in shares of Celcuity in the third quarter valued at approximately $36,236,000. Alliancebernstein L.P. increased its stake in shares of Celcuity by 2,208.6% during the third quarter. Alliancebernstein L.P. now owns 652,649 shares of the company's stock worth $32,241,000 after purchasing an additional 624,379 shares during the period. Finally, Soleus Capital Management L.P. increased its stake in shares of Celcuity by 17.0% during the second quarter. Soleus Capital Management L.P. now owns 3,011,818 shares of the company's stock worth $40,208,000 after purchasing an additional 437,696 shares during the period. 63.33% of the stock is owned by institutional investors.
About Celcuity
(
Get Free Report)
Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.
Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
